Beginning in 2009, studies of the humoral responses of HIV ‐positive individuals have led to
the identification of scores, if not hundreds, of antibodies that are both broadly reactive and …

Most neutralizing antibodies act at the earliest steps of viral infection and block interaction of
the virus with cellular receptors to prevent entry into host cells. The inability to induce …

Individuals with potential exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
do not necessarily develop PCR or antibody positivity, suggesting that some …

Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans.
Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detected …

A cure for HIV-1 remains unattainable as only one case has been reported, a decade ago 1
, 2 . The individual—who is known as the ‘Berlin patient’—underwent two allogeneic …

Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …

To evaluate these risks, we enrolled 200 patient-facing HCWs between March 26 and April 8,
2020, in SARS-CoV-2 Acquisition in Frontline Healthcare Workers—Evaluation to inform …

Broadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env)
trimer are the most common bnAbs induced during infection, making them promising …

The development of stabilized recombinant HIV envelope trimers that mimic the virion surface
molecule has increased enthusiasm for a neutralizing antibody (nAb)-based HIV vaccine. …

SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, and amino
acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics …